Drug intelligence / Profile preview

PHB-050

Development stage: Unknown
Lead developer: Poplar Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PHB-050 is a next-generation anti-IgE antibody developed by Poplar Therapeutics (formerly Phylaxis Bioscience). It is currently in a Phase 1 clinical trial for the treatment of food allergies and other atopic conditions. The drug aims to be a best-in-class therapy, particularly for patients with highly elevated IgE levels who do not respond well to existing treatments like omalizumab.

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on PHB-050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHB-050.